secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001213900-25-076066
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q2 net loss $6.4M; requests FDA Type A meeting for CRL on OLC
-----------------------------------------------------------------------

- Net loss of $6.4M vs net income of $3.0M in Q2 2024; R&D expenses down to $1.8M.
- Cash and equivalents $22.3M as of June 30, 2025; runway expected into H2 2026.
- Type A meeting requested with FDA to resolve CRL for oxylanthanum carbonate (OLC).
- Pivotal OLC data published in CJASN: >90% patients achieved phosphate control with low pill burden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/0001213900-25-076066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/ea0253163-8k_unicy.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-076066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer